Ubs Oconnor LLC Scholar Rock Holding Corp Transaction History

Ubs Oconnor LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$13.2 - $17.76 $577,513 - $777,017	-43,751 Reduced 51.39%	41,378 $734,000
Q4 2023 Feb 14, 2024	SELL	$6.52 - $20.32 $830,987 - $2.59 Million	-127,452 Reduced 59.95%	85,129 $1.6 Million
Q3 2023 Nov 14, 2023	BUY	$6.02 - $7.76 $60,199 - $77,600	10,000 Added 4.94%	212,581 $1.51 Million
Q2 2023 Aug 14, 2023	BUY	$5.79 - $9.11 $1.17 Million - $1.85 Million	202,581 New	202,581 $1.53 Billion
Q1 2023 May 15, 2023	BUY	$7.36 - $12.72 $47,508 - $82,107	6,455 Added 5.0%	135,556 $1.08 Million
Q4 2022 Feb 14, 2023	BUY	$7.02 - $9.76 $139,354 - $193,745	19,851 Added 18.17%	129,101 $0
Q3 2022 Nov 14, 2022	SELL	$5.33 - $11.3 $30,647 - $64,975	-5,750 Reduced 5.0%	109,250 $757 Million
Q2 2022 Aug 12, 2022	BUY	$4.66 - $13.96 $535,900 - $1.61 Million	115,000 New	115,000 $631,000

174

75.4M

151K

40.1K

Ticker SRRK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,640,600
Market Cap $1.57B
Description
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clini...

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

Stay updated on Ubs Oconnor LLC with notifications on news.